Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

"The ability to detect advanced precancerous lesions and in particular advanced adenomas as part of a colorectal screening test is critical to drive a paradigm shift in current frontline screening options," said Dr Moritz Eidens, Chief Scientific Officer at Mainz Biomed. "We know that patients with advanced adenomas have an increased risk of developing colorectal cancer. The significant improvement in AA sensitivity compared to other non- invasive tests currently available combined with the excellent sensit ...